Trial of the efficacy and safety of CG428 lotion against the adjuvant chemotherapy induced alopecia in breast cancer patients.

Trial of the efficacy and safety of CG428 lotion against the adjuvant chemotherapy induced alopecia in breast cancer patients. - ALOBRCA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026955

Enrollment

100

Registered

2017-04-11

Start date

2017-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Start using CG428 before the beginning of (neo)adjuvant chemotherapy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) pathologically proven breast cancer 2) patients who are planned to receive anthracyclin and taxman regimen (neo)adjuvant chemotherapy. Trastuzumab usage is not restricted. 3) ECOG Performance status (PS) 0-2 4) Able to give written informed consent.

Exclusion criteria

Exclusion criteria: 1) Known allergy or hypersensitivity to some components of CG428. 2) Patients with recent (within 3 months) usage of other anti-hair-loss treatments. 3) Previous use of other anti-hair-loss treatment or hair growth treatment.

Design outcomes

Primary

Measure	Time frame
the rate of candidates who could take off their wig at twelve months after chemotherapy ends.	—

Secondary

Measure	Time frame
duration of chemotherapy alopecia symptoms(itching, pain of the skin) nail change AE assessment using Olsen/Canfield visual analog scale HRQOL	—

Countries

Japan

Contacts

Public ContactYasuyuki Kojima

St.Marianna University School of Medicine Breast and Endocrine Surgery

kojiyasu@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026